Immunovant (IMVT) Research & Development (2018 - 2026)

Immunovant has reported Research & Development for 9 years, with the latest figure at $142.3 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 51.93% year-over-year to $142.3 million; the trailing twelve-month figure through Mar 2026 stood at $456.7 million (up 26.53% YoY), and the FY2026 full-year result was $456.7 million, up 26.53% from the prior year.
• Research & Development for Q1 2026 stood at $142.3 million, up from $98.9 million in the prior quarter.
• The five-year high for Research & Development was $142.3 million in Q1 2026, with the low at $28.4 million in Q2 2022.
• Historically, Research & Development has averaged $71.9 million across 5 years, with a median of $66.1 million in 2024.
• Annual changes were most pronounced in 2024 — Research & Development soared 102.82% — and 2025, when it increased 4.66%.
• Immunovant's Research & Development stood at $42.3 million in 2022, then increased by 14.4% to $48.3 million in 2023, then soared by 95.54% to $94.5 million in 2024, then gained by 4.66% to $98.9 million in 2025, then jumped by 43.83% to $142.3 million in 2026.
• The last three Research & Development figures came in at $142.3 million (Q1 2026), $98.9 million (Q4 2025), and $114.2 million (Q3 2025), per Business Quant data.